Tracon Pharmaceu Stock Price, News & Analysis
Company Description
Tracon Pharmaceu (OTC: TCON) is a publicly traded biotechnology company in the Biological Products, (no Disgnostic Substances) sector. The company has a market capitalization of $4.3M, ranking #6,783 among all listed U.S. companies by market cap.
TCON stock has declined 99.2% over the past year. Shares last traded at $0.0322.
This page provides a comprehensive overview of TCON stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Tracon Pharmaceu (TCON) stock last traded at $0.0322. Over the past 12 months, the stock has lost 99.2%. At a market capitalization of $4.3M, TCON is classified as a micro-cap stock with approximately 3.4M shares outstanding.
Latest News
Tracon Pharmaceu has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 6 with negative movement. Key topics include clinical trial, earnings, conferences, stock split. View all TCON news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
TCON Company Profile & Sector Positioning
Tracon Pharmaceu (TCON) operates in the Biotechnology industry within the broader Biological Products, (no Disgnostic Substances) sector and is listed on the OTC.
Investors comparing TCON often look at related companies in the same sector, including Globestar Therapeutics Corp (GSTC), Endonovo Therape (ENDV), Panbela Therapeutics Inc (PBLA), Trevena Inc (TRVN), and Vincerx Pharma Inc (VINC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TCON's relative position within its industry.